GSK has gained US FDA breakthrough therapy designation for GSK'227 to treat adults with relapsed or refractory osteosarcoma.

Orna will receive a $65m upfront payment and is eligible to receive potential milestone payments and royalties.

Araris will use its linker technology to generate multi-warhead ADCs for “undisclosed targets” provided by Chugai.

As part of the agreement, Sanofi will provide Alloy with upfront license fees and near-term preclinical milestone payments up to $27.5m.

With clinical trials facing multiple challenges, digital solutions could provide the answer. We identify the key trends to watch in 2025.